合作
Pfizer signs research collaboration and license deal with Enodia Therapeutics for Sec61 inhibitors
Enodia Therapeutics entered a research collaboration and license agreement with Pfizer to discover and develop Sec61 inhibitor small molecules against multiple collaboration targets; after the collaboration term Pfizer will be responsible for all clinical, manufacturing, regulatory and commercial activities. Enodia will receive an upfront payment and is eligible for milestone payments and tiered royalties, bringing the total potential value to more than $500 million.
文章預覽
Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules Oct 13, 2026 | Featured , Press release PARIS – Oct. 13, 2026 – Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, today announced it has entered into a research collaboration and license agreement with Pfizer Inc. to discover and develop Sec61 inhibitors. The collaboration aims to accelerate the discovery and advancement of novel small-molecule therapeutics leveraging En…